Skip to content

Trial of treatment of vaginal intraepithelial neoplasia (VAIN)

Randomized trial of treatment of vaginal intraepithelial neoplasia (VAIN): laser vaporization and imiquimod

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN23349576
Enrollment
60
Registered
2016-01-18
Start date
2016-01-01
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal intraepithelial neoplasia (VAIN) Cancer Vaginal intraepithelial neoplasia (VAIN)

Interventions

Patients enrolled in the study will have an HPV sample taken (with a brush) in addition to the routine samples during an outpatient colposcopy visit. Enrolled patients will be randomized into two grou

Sponsors

Helsinki University Hospital, Women's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Over 18 years of age 2. Histological diagnosis of VAIN 2-3 3. Histological diagnosis of VAIN 1, which has been expectantly managed for two years

Exclusion criteria

Exclusion criteria: 1. Pregnancy or lactation 2. Lack of reliable contraception in premenopausal patients 3. Known HIV infection 4. Vaginal cancer

Design outcomes

Primary

MeasureTime frame
1. Histological regression (defined as VAIN 1 or less), assessed from punch biopsies 2. HPV clearance, assessed via HPV genotyping from cervical or vaginal brush samples Measured at 2, 4 and 6 months

Secondary

MeasureTime frame
1. Complete histological regression, assessed from punch biopsies 2. Tolerability of treatment, assessed based on adverse effect reporting on a standardized form from the patients Measured at 2, 4 and 6 months

Countries

Finland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 16, 2026